Pneumonia Acquired in the Community Through Drug-Resistant Streptococcus pneumoniae
- 1 June 1999
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 159 (6) , 1835-1842
- https://doi.org/10.1164/ajrccm.159.6.9808049
Abstract
The aim of the study was to determine the incidence of and risk factors for drug resistance of Streptococcus pneumoniae, and its impact on the outcome among hospitalized patients of pneumococcal pneumonia acquired in the community. Consecutive patients with culture-proven pneumococcal pneumonia were prospectively studied with regard to the incidence of pneumococcal drug resistance, potential risk factors, and in-hospital outcome variables. A total of 101 patients were studied. Drug resistance to penicillin, cephalosporin, or a macrolide drug was found in pneumococci from 52 of the 101 (52%) patients; 49% of these isolates were resistant to penicillin (16% intermediate resistance, 33% high resistance), 31% to cephalosporin (22% intermediate and 9% high resistance), and 27% to a macrolide drug. In immunocompetent patients, age > 65 yr was significantly associated with resistance to cephalosporin (odds ratio [OR]: 5.0; 95% confidence interval [CI]: 1.3 to 18.8, p = 0. 01), and with the presence of > 2 comorbidities with resistance to penicillin (OR: 4.7; 95% CI: 1.2 to 19.1; p < 0.05). In immunosuppressed patients, bacteremia was inversely associated with resistance to penicillin and cephalosporin (OR: 0.04; 95% CI: 0.003 to 0.45; p < 0.005; and OR: 0.46; 95% CI: 0.23 to 0.93; p < 0.05, respectively). Length of hospital stay, severity of pneumonia, and complications were not significantly affected by drug resistance. Mortality was 15% in patients with any drug resistance, as compared with 6% in those without resistance. However, any drug resistance was not significantly associated with death (relative risk [RR]: 2. 5; 95% CI: 0.7 to 8.9; p = 0.14). Moreover, attributable mortality in the presence of discordant antimicrobial treatment was 12%, as compared with 10% (RR: 1.2; 95% CI: 0.3 to 5.3; p = 0.67) in the absence of such treatment. We conclude that the incidence of drug-resistant pneumococci was high. Risk factors for drug resistance included advanced age, comorbidity, and (inversely) bacteremia. Outcome was not significantly affected by drug resistance.Keywords
This publication has 19 references indexed in Scilit:
- The Clinical Relevance of Antibiotic Resistance in the Management of Pneumococcal PneumoniaClinical Pulmonary Medicine, 1997
- Risk Factors for Isolation of Streptococcus pneumoniae with Decreased Susceptibility to Penicillin G from Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1996
- Epidemiological Features of and Risk Factors for Infection by Streptococcus pneumoniae Strains with Diminished Susceptibility to Penicillin: Findings of a French SurveyClinical Infectious Diseases, 1996
- Predictive Factors for Invasive Disease Due to Penicillin-Resistant Streptococcus pneumoniae: A Population-Based StudyClinical Infectious Diseases, 1994
- Antimicrobial Resistance in Streptococcus pneumoniae: An Epidemiological Survey in France, 1970-1990Clinical Infectious Diseases, 1992
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- The Role of Human Immunodeficiency Virus Infection in Pneumococcal Bacteremia in San Francisco ResidentsThe Journal of Infectious Diseases, 1990
- New and Emerging Etiologies for Community-Acquired Pneumonia with Implications for TherapyMedicine, 1990
- Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Isolates Causing Systematic Infections in Spain, 1979-1989Clinical Infectious Diseases, 1990
- Risk Factors and Response to Antibiotic Therapy in Adults with Bacteremic Pneumonia Caused by Penicillin-Resistant PneumococciNew England Journal of Medicine, 1987